Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
Brief Summary: The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management.


Options:
A: Arm Label: Observation (Prompt Sham); Type: SHAM_COMPARATOR; Interventions: Procedure: Prompt Sham, Procedure: Deferred laser, Drug: Deferred aflibercept | Arm Label: Prompt aflibercept; Type: EXPERIMENTAL; Interventions: Drug: Prompt aflibercept, Procedure: Deferred laser, Drug: Deferred aflibercept | Intervention Type: PROCEDURE; Name: Prompt Sham; Assigned to Arm(s): Observation (Prompt Sham) | Intervention Type: DRUG; Name: Prompt aflibercept; Assigned to Arm(s): Prompt aflibercept | Intervention Type: PROCEDURE; Name: Deferred laser; Assigned to Arm(s): Observation (Prompt Sham), Prompt aflibercept | Intervention Type: DRUG; Name: Deferred aflibercept; Assigned to Arm(s): Observation (Prompt Sham), Prompt aflibercept
B: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
C: Arm Label: Dosing regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal aflibercept injection [IAI] | Arm Label: Dosing regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal aflibercept injection [IAI] | Arm Label: Dosing regimen 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham | Intervention Type: DRUG; Name: Intravitreal aflibercept injection [IAI]; Assigned to Arm(s): Dosing regimen 1, Dosing regimen 2 | Intervention Type: DRUG; Name: Sham; Assigned to Arm(s): Dosing regimen 3
D: Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP

Answer: B